Business Daily Media

Men's Weekly

.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

  • Written by ACN Newswire - Press Releases

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

TOKYO, Feb 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2,

Read more //?#

Global Thryv voices bring a sharper lens to International Women’s Day

Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...

AI curiosity fuels new wave of employee-led innovation in Australia

Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...

Is your search bar your competitor’s best salesperson?

A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...

AIIMS Group and AdVisible merge

Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience     ...

Block's layoffs are a design win. Here's why

We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...

Why I Decided to Build a Better Way to Build Homes

Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...